Finance entity
All 3 tracked stories fall under one category: markets. Of the tracked stories, 3 of 3 also mention Terns Pharmaceuticals, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 151-day span. The busiest single day carried 2.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 3 tracked stories fall under one category: markets. Of the tracked stories, 3 of 3 also mention Terns Pharmaceuticals, the most common co-covered peer. That works out to roughly 0.1 stories per week across a 151-day span. The busiest single day carried 2. At 7.3, the average consequence score sits above the same-window beat average of 6.1. Each story carries 2 original sources on average, compared with 2.9 for the broader beat in this window. We currently track 3 Finance stories that mention Keytruda, published between March 25, 2026 and August 22, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 1559 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Keytruda. Shared-story counts are live from our verified record — not editorial picks.
Argus raised Merck's price target to $145 on pipeline depth and M&A, while Merck disclosed a small strategic stake in Evaxion. For investors, the story is the huge gap between a mega-cap's $16.6 billion quarter and a micro-cap's cash-burning AI bet.
Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion, securing a high-potential leukemia treatment. The deal is a strategic move to diversify Merck's oncology portfolio as it prepares for the 2028 patent expiration of its top-selling drug, Keytruda.
Merck has agreed to acquire Terns Pharmaceuticals for $6.7 billion in cash to bolster its oncology pipeline ahead of the 2028 patent expiration for its blockbuster drug, Keytruda. The deal centers on TERN-701, a promising leukemia treatment that positions Merck to compete directly with established players like Novartis.
Keytruda is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
